Sponsored

Radiopharm (ASX:RAD) secures AU$1.56Mn tax refund for FY22 R&D activities - Kalkine Media

March 28, 2023 11:25 AM AEDT | By Ankit Sethi
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights 

  • The tax refund would provide funding for continued development of the company’s portfolio of radiopharmaceutical products
  • Radiopharm recently announced a two-year partnership with cancer research centre GenesisCare
  • The company is set to attend the Jefferies Radiopharma Innovation Summit in New York next month

Australia's oncology space player Radiopharm Theranostics (ASX: RAD) has updated the market on research and development (R&D) tax refund. The company's R&D works during the 2022 financial year have been recognised, and a tax refund of over AU$1.56 million has been released in favour of RAD.

Recently, the company had also informed about its collaboration with GenesisCare for Phase 1 clinical trials of radiopharmaceutical nanobodies in Australia.

RAD's shares traded at AU$0.17 at the time of writing on 28 March 2023.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.